Emergent BioSolutions | EBS - 股票



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 386.8M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


股票 更改 日
Acadia Pharmaceuticals USD 108.67M 77.1M 2026-06
Akebia Therapeutics USD 13M 2.61M 2026-03
ALKERMES USD 298.96M 37.75M 2026-06
Alnylam Pharmaceuticals USD 97.11M 103.04M 2026-06
Amarin USD 164.07M 19.51M 2026-06
ANI Pharmaceuticals USD 143.47M 401K 2026-03
BioMarin Pharmaceutical USD 1.27B 25.66M 2026-03
Coherus Biosciences USD 3.17M 1.12M 2025-12
Emergent BioSolutions USD 328.9M 25.2M 2023-12
Exelixis USD 26.6M 4.92M 2026-03
Glaxosmithkline GBP 6.16B 39M 2026-03
Heron Therapeutics USD 54.57M 2.33M 2022-12
Ionis Pharmaceuticals USD 50.83M 45.28M 2026-06
Lexicon Pharmaceuticals USD 276K 5K 2026-03
Lonza CHF 1.68B 163M 2025-12
Merck USD 6.48B 179M 2026-03
Moderna USD 280M 134M 2026-06
Myriad Genetics USD 30.6M 2.7M 2026-06
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 104.2M 39.7M 2026-06
Pacira USD 134.57M 15.8M 2026-06
Pfizer USD 9.94B 722M 2026-06
PTC Therapeutics USD 91.35M 15.79M 2026-06
Sanofi EUR 24.12B 620M 2026-06
Sarepta Therapeutics USD 1B 86.37M 2026-03
United Therapeutics USD 193.8M 15.5M 2026-06
Vanda Pharmaceuticals USD 1.85M 190K 2025-12